Heterocyclic Compounds as CDK9 Inhibitors: Structural Diversity, Mechanism of Action, and Therapeutic Potential in Cancer and Beyond

被引：0
|
作者：
Bose, Kuntal [1 ]
Shajahan, Afiya [1 ]
Sreekumar, Nandana [1 ]
Aneesh, T. P. [1 ]
机构：
[1] Amrita Vishwa Vidyapeetham, Amrita Sch Pharm, Dept Pharmaceut Chem, AIMS Hlth Sci Campus, Kochi 682041, Kerala, India
来源：
CHEMISTRY & BIODIVERSITY | 2025年 / 22卷 / 01期
关键词：
CDK-9; P-TEFb; RNA polymerase-II; CTD; DEPENDENT KINASE INHIBITOR; CELL-CYCLE ARREST; R-ROSCOVITINE; PHASE-I; ANTITUMOR-ACTIVITY; TARGETING CDK9; DISCOVERY; FLAVOPIRIDOL; APOPTOSIS; COMBINATION;
D O I：
10.1002/cbdv.202401797
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Cyclin-dependent kinases (CDKs) are crucial proteins involved in key cellular processes, such as cell division and transcription. Their dysregulation plays a significant role in cancer development. Inhibiting cyclin-dependent kinase 9 (CDK9) impacts several survival pathways in cancer cells, presenting a promising therapeutic approach for various cancers. CDK9, in association with cyclin T1, forms the positive transcription elongation factor b (P-TEFb) complex, which phosphorylates the C-terminal domain (CTD) of RNA polymerase II (Pol II). This phosphorylation promotes the transition from transcription initiation to elongation. This review examines recent advancements in CDK9 modulators, with a particular emphasis on compounds currently in clinical trials.
引用
收藏
页数：16
相关论文
共 50 条
  • [21] Molecular Insights on Selective and Specific Inhibitors of Cyclin Dependent Kinase 9 Enzyme (CDK9) for the Purpose of Cancer Therapy
    Karati, Dipanjan
    Mahadik, Kaka Saheb Ramoo
    Trivedi, Piyush
    Kumar, Dileep
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (04) : 383 - 403
  • [22] Synthesis and biological evaluation of seliciclib derivatives as potent and selective CDK9 inhibitors for prostate cancer therapy
    Alsfouk, Aisha A.
    Alshibl, Hanan M.
    Altwaijry, Najla A.
    Alsfouk, Bshra A.
    Al-Abdullah, Ebtehal S.
    MONATSHEFTE FUR CHEMIE, 2021, 152 (01): : 109 - 120
  • [23] Synthesis and biological evaluation of seliciclib derivatives as potent and selective CDK9 inhibitors for prostate cancer therapy
    Aisha A. Alsfouk
    Hanan M. Alshibl
    Najla A. Altwaijry
    Bshra A. Alsfouk
    Ebtehal S. Al-Abdullah
    Monatshefte für Chemie - Chemical Monthly, 2021, 152 : 109 - 120
  • [24] CDK7 in breast cancer: mechanisms of action and therapeutic potential
    Gong, Ying
    Li, Huiping
    CELL COMMUNICATION AND SIGNALING, 2024, 22 (01)
  • [25] Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer
    Blake, Devon R.
    Vaseva, Angelina V.
    Hodge, Richard G.
    Kline, McKenzie P.
    Gilbert, Thomas S. K.
    Tyagi, Vikas
    Huang, Daowei
    Whiten, Gabrielle C.
    Larson, Jacob E.
    Wang, Xiaodong
    Pearce, Kenneth H.
    Herring, Laura E.
    Graves, Lee M.
    Frye, Stephen V.
    Emanuele, Michael J.
    Cox, Adrienne D.
    Der, Channing J.
    SCIENCE SIGNALING, 2019, 12 (590)
  • [26] Histone deacetylase inhibitors:: mechanism of action and therapeutic use in cancer
    Martinez-Iglesias, Olaia
    Ruiz-Llorente, Lidia
    Sanchez-Martinez, Ruth
    Garcia, Laura
    Zambrano, Alberto
    Aranda, Ana
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2008, 10 (07): : 395 - 398
  • [27] PHOSPHODIESTERASE-IV INHIBITORS - STRUCTURAL DIVERSITY AND THERAPEUTIC POTENTIAL IN ASTHMA
    CAVALLA, D
    FRITH, R
    CURRENT MEDICINAL CHEMISTRY, 1995, 2 (01) : 561 - 572
  • [28] Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer
    Olaia Martínez-Iglesias
    Lidia Ruiz-Llorente
    Ruth Sánchez-Martínez
    Laura García
    Alberto Zambrano
    Ana Aranda
    Clinical and Translational Oncology, 2008, 10 : 395 - 398
  • [29] Novel tacrine derivatives as potential CDK9 inhibitors with low cholinesterase inhibitory properties: design, synthesis, and biological evaluation
    Liu, Wenwu
    Huang, Yaoguang
    Wu, Limeng
    Liu, Wenjie
    Jiang, Xiaowen
    Xu, Zihua
    Zhao, Qingchun
    NEW JOURNAL OF CHEMISTRY, 2022, 46 (40) : 19342 - 19356
  • [30] CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents
    Anshabo, Abel Tesfaye
    Milne, Robert
    Wang, Shudong
    Albrecht, Hugo
    FRONTIERS IN ONCOLOGY, 2021, 11
12345